ReviewCardiovascular toxicology2026
Ferroptosis-Mitochondrial Crosstalk in Cardiomyocyte Death: The Cardiomyocyte Ferroptotic Amplification Circuit (CFAC) as a Proposed, Testable Systems Framework.
Review in Cardiovascular toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiomyocyte loss in heart failure is conventionally attributed to apoptosis and necrosis, yet neither fully accounts for the metabolic signature, irreversibility, or magnitude of cell loss in ischemia-reperfusion injury, diabetic cardiomyopathy, or pressure-overload failure. Ferroptosis and mitochondrial dysfunction each contribute to cardiac injury, but their mechanistic interdependence has not been formally modeled. We propose, explicitly as a hypothesis-generating model rather than an established mechanism, the Cardiomyocyte Ferroptotic Amplification Circuit (CFAC), in which ferroptosis and mitochondrial dysfunction are reciprocally reinforcing rather than parallel. CFAC comprises three interlocked positive-feedback loops: an inorganic loop (mitochondrial iron → Fenton ROS → Fe-S cluster disassembly → labile iron); an organic loop (mitochondrial ROS → PE-PUFA peroxidation → electron transport chain adduction → ROS); and a proposed proteotoxic loop (phospholipid hydroperoxide accumulation → hypothesized GPX4 inactivation by electrophilic lipid-peroxidation products → further peroxide accumulation). We postulate that cyclophilin D-regulated permeability transition marks a terminal tipping point at which loss of membrane potential and matrix glutathione extinguishes residual GPX4 activity. The model predicts that partial suppression of two or more loops may outperform complete blockade of one loop, and defines a candidate CFAC-active cardiac phenotype, which requires prospective validation and is proposed neither as a diagnostic entity nor as a distinct cardiomyopathy. Individual components are supported by published experimental work; their integration into a single coupled, nonlinear, threshold-dependent circuit is our inference and is presently unproven. Bistability in the strict sense (two stable states with a hysteretic return path) is a proposed property of that circuit that has not been demonstrated in any system; the framework is therefore described throughout as a proposed nonlinear threshold model, and the experiment that would test bistability directly is specified in Sect. 8.5. The framework is accordingly stated as three nested claims of decreasing security, namely a coupled and threshold-dependent circuit, a bistable and hysteretic extension of it, and a translational phenotype hypothesis, each with its own prespecified falsification criterion, so that a negative result identifies which claim it has ended (Sect. 8.1). We therefore present CFAC as a falsifiable framework and specify the experiments that would confirm or refute it.
Indexed as
Identifiers
42726159What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.